A new drug discovery method has identified a naturally occurring metabolite that converts ‘bad’ fat to ‘good’ fat. The metabolite, called ‘betahydroxybutyrate’ (BHB), is produced by the body during periods of fasting or calorie restriction and is known to have anti-inflammatory and anti-oxidant effects.
Researchers believe that BHB could be used to treat obesity and related diseases, such as type 2 diabetes, by improving the body’s ability to cope with fat storage. BHB is thought to work by activating a pathway that converts ‘bad’ fat into ‘good’ fat. This ‘good’ fat is known as ‘brown’ fat, which is more metabolically active and burns calories rather than storing them.
In a recent study, mice that were fed a high-fat diet and injected with BHB showed increased levels of brown fat and improved glucose tolerance. The study’s lead author, Dr. supplements 2018 Patrice Cani, said that the findings “support the therapeutic potential of BHB to treat human obesity and related disorders.”
While more research is needed to confirm the effects of BHB in humans, the findings of this study suggest that this metabolite could be a promising new treatment for obesity and related diseases.
A recent study has found a potential new target for the treatment of obesity and related diseases. The study, published in the journal Nature Medicine, identified a naturally occurring metabolite that appears to convert ‘bad’ fat to ‘good’ fat.
This new finding could lead to the development of drugs that would specifically target this metabolite, which could potentially be used to treat obesity and related conditions. The study used a new drug discovery method that combines approach
obesity is a global epidemic, with more than 1.9 billion adults worldwide classified as overweight or obese. Obesity is a major risk factor for a number of chronic diseases, including type 2 diabetes, cardiovascular disease, and certain cancers.
The current therapeutic options for obesity are limited and are associated with significant side effects. Therefore, there is a need for new and effective treatments for this condition.
The new study used a drug discovery method known as activity-based protein profiling (ABPP) to identify a new target for the treatment of obesity. ABPP is a powerful tool that can be used to identify small molecules that modulate the activity of a particular protein.
In this study, the researchers used ABPP to identify a naturally occurring metabolite that appears to modulate the activity of a protein called carnitine palmitoyltransferase 1 (CPT1). CPT1 is a key enzyme in the process of lipid metabolism.
The researchers found that this metabolite, which they named ‘CPT1-AM’, activates CPT1 and promotes the conversion of ‘bad’ fat to ‘good’ fat. ‘Bad’ fat is stored in the body as triglycerides, while ‘good’ fat is used for energy.
This finding suggests that CPT1-AM could be a potential target for the treatment of obesity and related conditions. The researchers are now working on developing drugs that specifically target CPT1-AM.
If successful, these drugs could be used to treat obesity and related conditions by specifically targeting the ‘bad’ fat in the body and converting it to ‘good’ fat. This would offer a new and effective treatment option for these conditions, with potentially fewer side effects than existing options.
